Apimeds Pharmaceuticals Announces CFO Appointment; Interim CFO Resigns

What Happened
Apimeds Pharmaceuticals US, Inc. filed an 8-K reporting that Interim Chief Financial Officer Erick Frim resigned effective immediately on September 29, 2026. The Board appointed Eric Sherb as the Company’s Chief Financial Officer effective October 1, 2026; Mr. Sherb will serve as the Company’s principal financial officer and principal accounting officer.

Key Details

• Erick Frim notified the Company of his resignation on September 29, 2026; the resignation was not due to any disagreement with the Company.
• Eric Sherb (age 40), a Certified Public Accountant with over 18 years of capital markets experience and founder of EMS Consulting Services (founded Jan 2019), was appointed on September 30, 2026, effective October 1, 2026.
• Employment Agreement effective October 1, 2026: base salary of $60,000 per year; does not include any equity awards that may be granted in the future.
• Mr. Sherb has served since February 2026 as fractional CFO of MindWave Innovations Inc. (a wholly owned subsidiary); that engagement will terminate upon his appointment. The Company reports no related-party transactions or family relationships requiring disclosure.

Why It Matters
A change in the principal financial and accounting officer is material for investors because the CFO is responsible for financial reporting, SEC filings and internal controls. The filing provides concrete facts about timing, compensation and Mr. Sherb’s background (CPA, audit and advisory experience), which investors can use to assess continuity in financial oversight. Investors should watch future filings for any additional compensation (e.g., equity awards) or further disclosures about financial reporting and controls.